Welcome to the website for Transregional Collaborative Research Center (CRC) SFB TR-128 Initiating/effector versus regulatory mechanisms in Multiple Sclerosis – progress towards tackling the disease. On this site you will find general information regarding the CRC as well as more specific information about its individual research projects.

Multiple Sclerosis (MS) is the most common chronic inflammatory disease of the central nervous system (CNS) in the western world and it leads to devastating disability in young adults, with only limited treatment options currently available. The socioeconomic burden of this disease is tremendous, since healthcare costs are very high and it affects decisions young patients must make for the rest of their lives. Findings in patients are a complex composite of inflammation (with demyelination, remyelination, axonal/neuronal damage) typically in subcortical, but also cortical, disseminated lesions as well as neurodegeneration. Remissions of clinical relapses point to repair capacities of the CNS, which exhibits strong interindividual and course dependent differences.

Heinz Wiendl

Frauke Zipp


Thu, 16/03/2017
SFB Scientists reprogram skin cells to brain cells to facilitate neurological research
Münster. (mfm/jr) Whether it be math, writing, reading or learning a new language: brain cells give us astonishing brainpower every day. When these cells are damaged by neurological diseases, cells cannot be simply sampled and analyzed in a petri dish. Scientists from the University of Münster and the Max Planck Institute for Molecular Biomedicine developed […]...more
Thu, 16/03/2017
11th CiM-IMPRS Graduate School Meeting in Muenster 2017
Münster. The Cluster of Excellence “Cells in Motion” hosts the 11th CiM-IMPRS Graduate School Meeting on April 26-28, 2017 at the Max Planck Institute for Molecular Biomedicine in Muenster. This international scientific meeting is organised by the PhD students of the Cells-in-Motion and the International Max Planck Research School Graduate Program. The purpose of this […]...more
Mon, 13/03/2017
How the understanding of MS pathways leads to the development of new therapies
Muenster. The pathways that lead to neurodegeneration in MS are still not fully known. Yet, the better they are understood, the better new MS therapies can interfere with these mechanisms of disease. In her lecture Dr. Susan Goelz, advisor on translational science at Oregon Health and Science University, will focus on the putative pathways of […]...more